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Summary
Introduction: New radiation therapy techniques seek to adapt dose distribution to three-
dimensional tumor geometry, so as to deliver the lowest possible dose to normal tissue and
at-risk organs. This is expected to enhance locoregional control and survival and to reduce
complications and thereby improve quality of life. Post-radiation xerostomia signiﬁcantly dete-
riorates quality of life.
Material and methods: New external radiation techniques (such as intensity-modulated confor-
mal radiation therapy, RapidArc VMAT arc therapy, tomotherapy, CyberKnife®, protontherapy,
use of carbon ions) applicable in ENT are reviewed.
Results: Preliminary data show interesting results in terms of salivary function with highlyProtontherapy;
Carbon ions;
Xerostomia
conformal techniques.
Conclusion: In France, assessment is ongoing, ﬁnanced under the Health Ministry’s ‘‘Support
for Expensive Innovatory Techni
teuses]), as routine use is growi
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achieve a speciﬁc dose distribution voxel-by-voxel within98
ntroduction
ew radiation therapy techniques seek to adapt dose distri-
ution to three-dimensional tumor geometry, so as to deliver
he lowest possible dose to normal tissue and at-risk organs.
his is expected to enhance locoregional control and survival
nd to reduce complications and thereby improve quality of
ife.
Post-radiation xerostomia signiﬁcantly deteriorates
uality of life [1—4]. The parotid glands produce most of
he stimulated salivary ﬂow, but the other salivary glands,
uch as the oral cavity accessory glands, contribute to the
roduction of non-stimulated saliva and conversely to the
ensation of chronic dry mouth. Apart from the case of radi-
tion treatment of salivary gland tumor and certain selected
umors (e.g., lateralized oropharynx T1 N0 tumor), where
adiation may be unilateral, 2D radiation treatment of head
nd neck cancer (HNC) is bilateral, and involves the parotids.
he dose delivered induces irreversible xerostomia.
One of the most important parameters in radiation plan-
ing (Fig. 1) is the critical dose delivered to healthy organs
nd the quality of contouring of organs receiving radia-
ion. Conservation of healthy organs has to be weighed
gainst oncological risk, which depends upon the initial can-
er grade: 60—70% of HNCs are grades III—IV and 30—40%
rades I—II. For locally advanced stages, current treatment
tandards recommend concomitant radiochemotherapy (iso-
ated or postoperative), which improves overall survival
nd locoregional control, but also increases certain forms
f late toxicity [5]. Certain medical treatments have been
ested for salivary function conservation, but results with an
ssociation of cytoprotectant (amifostine, pilocarpine) and
lassic radiation therapy are contradictory and treatment is
ostly and sometimes poorly tolerated [6—11] with, in the
ase of pilocarpine, only transitory beneﬁt.
The salivary glands are better visualized on MRI than on
T [12]. MRI may be associated to dosimetric scan. PET scan
o determine target volumes is currently under study [13].
The sensitivity pattern of radiation varies with tissue
rchitecture [14]. Architecture is said to be in series when
rgan function depends on each functional subunit: the
rgan is seen as a chain of connected links, a break in any
ne of which leads to loss of function. A typical example is
one-marrow: radiationmyelopathy, while exceptional, may
nduce tetraplegia at an interval of between six months and
everal years. The parotid glands have an architecture in
arallel, and come in pairs. It may be reasonable to sacri-
ce one parotid if conservation would incur a risk in terms
f ipsilateral tumor or lymph-node volume, while at least
artially conserving contralateral parotid volume. The data
nitially established for the parotids by Eisbruch were based
n the ratio of stimulated to baseline ﬂow, determining a
ean dose of ≤26Gy to recover the initial ﬂow rate at 12
onths [15,16]; this threshold value varies between studies.
he threshold can also be determined on a dose-volume his-
ogram (a decision-making tool in radiotherapy; see Fig. 1)
n terms of the percentage (e.g., 50%) of the contralateral
arotid gland receiving >30Gy radiation. The other salivary
lands, such as the accessory glands, also contribute to non-
timulated ﬂow and to chronic dry mouth, but have as yet
een little studied.
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volution of radiation techniques
o-called ‘‘cobalt bombs’’ have been withdrawn from the
echnical arsenal in France: although useful in certain super-
cial tumors, they did not allow precise dose adjustment
ith respect to cutaneous and mucosal toxicity, which
as high. Cobalt therapy was therefore gradually replaced
y 3D conformal techniques (3D-CR), including intensity-
odulated conformal radiation therapy (IMRT). Multi-leaf
ollimators (MLC) are one of the major innovations of the
ast 30 years: initially designed to replace the individualized
ead caches focusing the beam, they contributed to the
evelopment of conformal radiation therapy and to the
erivative applications involving beam modulation that led
o IMRT.
MRT
MRT has been used in France since the ﬁrst decade
f this century, at ﬁrst for rhinopharyngeal and oropha-
yngeal cancer and with the aim of conserving salivary
unction [17]. Most studies have been retrospective and
on-randomized, as the technique quickly came into rou-
ine use. Some studies focused on salivary ﬂow, but often
ith non-standardized measurement methods and some-
imes without taking locoregional control into account,
lthough the goal of conserving salivary function is appli-
able only to the extent that oncological control is not
mpaired. The advantage of IMRT and its derivatives (arc
herapy and tomotherapy) is to generate isodoses that are
‘sculpted’’ to complex concave forms, with better confor-
ation than in 3D radiation. This ballistic advantage serves
ell in the treatment of lateralized and/or early-stage
umor, to conserve salivary function where oncologically
easible, or on the other hand to treat locally advanced
umors in which it would be impossible to deliver a full dose
o the entire tumor volume in 2D due to neighboring struc-
ures such as the bone-marrow in case of tumor ﬁxed to the
revertebral planes. IMRT reduces the high-dose volume and
ay reduce the rate of complications. It also allows dose
scalation, so as to enhance oncologic efﬁcacy [18—20].
hese advantages remain to be demonstrated clinically in
rospective randomized comparative studies versus stan-
ard 3D techniques, and should result in an improvement
n quality of life.
To ensure precision of treatment and constant position-
ng, restraints such as masks, arm-rests and toe clips are
sed. The schematized principles of IMRT executed in ‘‘step-
nd-shoot’’ (stopping the shoot at each leaf movement) or
‘dynamic’’ mode (continuous shooting simultaneous to the
ollimator movements) are based on increasing the beam
umber (ﬁve to nine, instead of three as in 2D radiation) and
umber of entry points (e.g., anterior beam), and imple-
enting dose ﬂuence (number of photons per unit area
er unit time) (Fig. 2): i.e., voxel-by-voxel dose modu-
ation. Modulation is achieved by mobilizing the MLCs toach beam. The resultant dose gradients are steep, unlike
ith radiation using two opposing parallel beams result-
ng in a homogeneous ‘‘tunnel’’ dose distribution. IMRT
mplements a novel inverse planimetric principle: clinical
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wFigure 1 Successive step
priorities, staged in terms of dose and volume, are selected
for healthy organs and target volumes; an algorithm enables
the desired clinical compromise to be approximated and
visualized as a dose-volume histogram with maximum, min-
imum, modal and mean doses and any other treatment
quality indices (which will not be detailed here). An order
of priority might, for example, be:
1) max. marrow dose <45Gy;
2) tumor ≥70Gy;
3) mean contralateral parotid dose ≤26Gy.
Thirteen IMRT studies (973 patients) were selected for
IMRT assessment by the French Health Authority in Decem-
ber 2006 [21]. Six studies demonstrated the interest of
IMRT over 2D techniques with respect to conservation of
salivary function (zero rate of grades 3—4 xerostomia in
Figure 2 Schematic representation of multi-leaf caches
(schematic explanation of dose ﬂuence) in IMRT.
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ix out of seven studies), with anti-tumor efﬁcacy compa-
able to that of 3D-RT (76—98% local control at 2 years,
n 11 studies). These were retrospective comparisons. The
rst recent randomized study, PARSPORT [22], demonstrated
he superiority of IMRT for conservation of salivary func-
ion (for comparable oncological results) in T1-4 N0-3 M0
ropharyngeal and hypopharyngeal tumor. IMRT involves a
earning-curve [23—27] for contouring, and the oncological
bjective of course remains primordial. The PARSPORT study
howed that the rate of grade ≥2 xerostomia at 1 year post-
rradiation was 50% lower with IMRT than with conventional
D and 3D radiations, with recovery continuing at 18 months,
hereas it stabilized using conventional techniques.
While dynamic IMRT is faster than the step-and-shoot
orm, loading the veriﬁcation network and recording the
eld parameters take an incompressible amount of time:
enerally, at least two patient slots (versus one in 2D);
reatment time (≈20—25min) thus limits mass implemen-
ation of IMRT. Since 2005, the technology has been
ptimized, with modulated arc therapy (RapidArcTM and
MATTM) and tomotherapy, also based on linear accelerators
enerating X-rays. When a radiation therapy department
pdates its external equipment, the choice between the
arious types of accelerator is based on several factors:
atient—treatment time, hardware costs and bunker size
very thick walls — up to several meters, including ﬂoor and
eiling — are needed for radioprotection in rooms housing
ccelerators).odulated arc therapy
MRT requires treatment beams to be sequenced one after
nother. For continuous sequencing, radiation with continu-
us accelerator-arm rotation was developed. This moreover
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advantage in ENT), the images are less affected by mate-Figure 3 Arc therapy equipment.
nables beam entry points to be multiplied, optimizing bal-
istics. The concept of ‘‘cyclotherapy’’ itself is not new, but
ts implementation was out-dated; the Varian corporation
eveloped a solution called RapidArcTM, performing IMRT in
otation and modulating the dose rate by modulating the
peed of rotation of the arm around the patient, with con-
inuous leaf movement [28] (Fig. 3). The Elekta corporation
eveloped a similar solution, with some technical variants,
nown as VMAT. Both of these modulated arc therapy devices
educe the number of monitor units and the processing time
a few minutes) compared to IMRT. Arc therapy can be used
or conservation of salivary function, with the possibility
f a more homogeneous dose distribution, fewer high-dose
reas, and better conformation to the salivary glands.
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omotherapy
omotherapy is another optimization of IMRT. Helical
omotherapy uses a linear accelerator ﬁtted to a ring turning
round the patient to combine cross-sectional image-guided
adiation therapy (IGRT) (CT type) and IMRT [29] (Fig. 4).
reatment was ﬁrst performed in the US in 2003 and in
urope in 2005. Tomotherapy is aid to be helical, as it is
ased on longitudinal translation of the table (on which the
atient lies) and rotation of the accelerator, with movement
f the leaves (two positions: open and closed) modulating
he beam. The 6MV X-ray beam is produced by a linear
lectron accelerator integrated in the ring. Leaf opening
ime is proportional to the desired radiation intensity for
ach part of the beam. The apparatus has the form of a
ing and resembles a large scanner. Examination time lasts
etween 20 and 30min, in two stages. Firstly, the scanning
tage checks the patient’s position ahead of treatment. The
reatment table may be repositioned in the light of any dis-
repancies between reference images and those acquired
uring this stage. Treatment is then performed, using the
easured corrections. The machine is quite noisy, with jerky
oises as the treatment beam is modiﬁed as the appara-
us rotates. Because of the ventilation, the patient has to
e well covered against the cold. The tomotherapy scan-
er uses treatment beam degradation to descend from 6 to
.5MV. The high energy of the megavoltage CT (MVCT) beam
ives lower contrast quality than obtained on kilovoltage
kVCT) images. On the other hand (and this is a signiﬁcantials with high atomic numbers, such as dental implants,
hich greatly artifact kVCT images such as those acquired
n classical CT dosimetry, which hamper the contouring of
rgans and neighboring tumor and the calculation of dose
apy equipment.
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distribution. Densities are assigned artiﬁcially in dosimetry,
to compensate for artifacts, and give false results for high-
density materials; the clinical dosage algorithms describe
interfaces with variable accuracy, failing at present to take
account of the increased dose at tissue/metal interfaces.
A preliminary study was run on 15 patients with ENT
cancer (six nasopharynx, ﬁve oropharynx, one parotid, two
larynx, one hypopharynx), mostly locally advanced in stage
and managed by tomotherapy over the period 2007—2008
with the aim of conserving the salivary glands [30]. Tar-
get volumes were contoured after fusion of CT, MRI and
PET images. The high-risk tumor target volume received
66—70Gy (2—2.3Gy/fr). Technetium-99 scintigraphy deter-
mined salivary excretion ahead of treatment and then every
six months for 18 months, with and without citric acid
stimulation. A mean 21Gy (range, 6—27) was delivered to
the right parotid and 21Gy (11—26) to the left. Results were
very encouraging in terms of salivary function [30].
Modulated arc therapy and tomotherapy are as yet rarely
available on the same radiation therapy site (investment
choice, as explained above). With now a few years’ hind-
sight, they can be said to provide quite comparable results.
Tomotherapy presently takes longer, but could be more
interesting for large volumes (e.g., locally advanced N+
rhinopharyngeal tumor).
Fractionated stereotactic radiation therapy
(CyberKnife®, microleaf accelerators)
Alongside IMRT techniques, whole-body stereotactic radia-
tion using CyberKnife® (Fig. 5) is promising in ENT oncology
[31]. The steep dose gradients make it easy to spare the sali-
vary glands. In HNC reirradiation (at least part of the volume
ﬁrst irradiated lies within the volume to be reirradiated),
preliminary results associating cetuximab and experience
using the French protocol CKNORERT demonstrated fea-
sibility, relatively good tolerance and encouraging results
in terms of response to stereotactic reirradiation in non-
operable recurrent HNC. CyberKnife® is increasingly used
in ﬁrst-intention curatives indications for primary localized
cancer. Its ﬁrst non-cranial applications were for non-
operable T1-2 lung cancer, but it is now being recommended
p
t
1201
or therapeutic trials as an alternative to surgery in operable
ases. CyberKnife® radiation may also be usefully associated
o other novel techniques such as IMRT and its deriva-
ives: these techniques are in fact complementary. IMRT
ses classical fractioning to treat relatively large volumes
ith segments that may exceed 40 cm. A booster dose
sing CyberKnife® may be applied to a limited volume,
nabling hypofractionation and dose escalation. Such opti-
ized conformation is especially useful in case of at-risk
tructures in the vicinity of the booster target. This kind of
esign is at phases II or III in several centers. The Rotterdam
eam is due to report on their phase II trial in oropharyn-
eal radiation (prophylactic lymph-node + oropharynx IMRT
ollowed by CyberKnife® booster to the macroscopic tumor
olume in three fractions with relative dose escalation),
ith results that seem to be better than with curietherapy
n terms of functional conservation (dysphagia, xerostomia)
nd with at least as good local control as with other tech-
iques [32]. These assessments for xerostomia are limited
t present, but the ballistic advantages of the CyberKnife®
echnique should allow better conservation of salivary func-
ion.
eutrontherapy
eutrontherapy was used in the late 1990s for certain indi-
ations such as non-operable cystic adenoid carcinoma, but
as abandoned due to excessive toxicity (strong biological
ffectiveness, which was dangerous in case of deep tumor,
iven the relatively poor ballistic performance) and equip-
ent cost.
adrontherapy (protons and carbon ions)
adrontherapy is a type of radiation therapy that uses the
onstituents of atomic nuclei (protons, neutrons) and, by
xtension, the nuclei themselves (helium, neon and, at
resent, especially carbon ions). Hadrontherapy (proton-
herapy [33] and carbon ions [34]) can be recommended
or radiation-resistant tumors in the vicinity of neuro-optic
tructures and in pediatrics, thanks to its ballistic advan-
ages (with conservation of salivary function as a corollary).
Protontherapy has been developing strongly over the last
ew years. The ballistic advantage of the Bragg peak enables
xcellent conformation. Increased dose at a given depth in
he tumor with a low exit dose behind the Bragg peak (Fig. 6)
llows healthy tissue to be spared. This feature has been
sed in the treatment of choroid melanoma, chordoma, and
hondrosarcoma of the base of the cranium and for pediatric
umor (the lower integral dose holding out the hope of a
educed incidence of secondary tumor, a key point in pedi-
trics). One technical innovation in protontherapy is the
ossibility of delivering dynamic beams, enabling intensity
odulation.
Carbon-ion hadrontherapy centers were ﬁrst installed
n Japan, and later in Germany. Equipment cost and size
resently limit extension, but can be expected to fall. The
herapeutic interest of carbon ions is two-fold:
) ballistic, with the Bragg peak, as for protons;
202
Figure 6 Bragg peak in hadrontherapy radiation: comparison
of deep dose distribution with other types of radiation treat-
ment.
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Rigure 7 Schematic representation of the various currently
vailable radiation techniques.
) radiobiological, cytotoxic efﬁcacy being much greater
than with X-photons and protons, which is of particular
interest for radioresistant tumors.
Carbon ions are thus well adapted to tumors where
ocoregional control is unlikely because of resistance to
urgery and radiation therapy. With the ballistic advan-
ages of protons and carbon ions, hadrontherapy shows great
otential for the conservation of salivary function.
Fig. 7 schematizes the role of the various techniques pre-
ented above.
imitations of the present methods of saliva
ssessment
alivary function assessment shows great inter- and intra-
ubject variability. Dosimetric studies have often been
imited to the parotid glands, whereas saliva assessment
ends to be global. Comparison across different radiation
herapy sites is difﬁcult. The submandibular and sublin-
ual glands may be contoured on dosimetric scan, but the
ccessory salivary glands scattered over the oral cavity can-J. Thariat et al.
ot be contoured with precision (small size, non-visible
n imaging, variable topography). Patient-questionnaires
n salivary function and quality of life and the Radiation
herapy Oncology Group (RTOG) and NCI Common Toxicity
riteria (CTC) scales are not highly reproducible. Secretion
1.5 L/day) is under complex sympathetic and parasympa-
hetic control. Secretion stimuli are not only gustatory but
lso tactile, mechanical, and psychological. Quantitative
easurement of stimulated and non-stimulated ﬂow varies
ver the nycthemeron and with feeding, medication intake,
nd psychological factors, even for a given subject, making
t difﬁcult to design a precise and reproductible method
f assessment. Salivary scintigraphy would seem to be the
ost objective criterion, but assesses only parotid and sub-
andibular gland function [30,35,36], and is not yet widely
sed. The interest of combining several methods remains to
e determined.
onclusion and perspectives
evelopments in radiation therapy hold out the hope of
mproving locoregional control while conserving salivary
unction in so far as this does not compromise the onco-
ogical objective. Underestimating a microscopic pathology
or the sake of the salivary glands necessarily increases
he risk of failure [37]. The new radiation techniques
blige the oncological radiation therapist to adhere to a
igorous methodology in deﬁning target volumes (expertise
n radioanatomy and the natural history of HNC). Quality of
ife can be expected to beneﬁt from the impact of these
ew techniques on late toxicity in case of bilateral irradia-
ion of the neck. Arc therapy and tomotherapy will probably
ecome routine in coming years and the indications for
tereotactic radiation and hadrontherapy will be extended.
ssessment of salivary function will need to be standardized,
robably by combining a number of subjective and objective
arameters and taking into account other salivary glands
han the parotids alone. Studies are presently ongoing of
he role of cytoprotectants, notably for N2c patients, and
f contralateral submaxillary gland transfer in N0-N1 and
2a-b patients undergoing bilateral irradiation [38—41].
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